Intercure
InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in the biomed sector. The company has a strategic alliance with… Read more
Intercure (INCR) - Net Assets
Latest net assets as of June 2025: ILA432.24 Million ILA
Based on the latest financial reports, Intercure (INCR) has net assets worth ILA432.24 Million ILA as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (ILA751.76 Million) and total liabilities (ILA319.52 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ILA432.24 Million |
| % of Total Assets | 57.5% |
| Annual Growth Rate | N/A |
| 5-Year Change | 36.14% |
| 10-Year Change | 3226.95% |
| Growth Volatility | 533.74 |
Intercure - Net Assets Trend (2008–2024)
This chart illustrates how Intercure's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Intercure (2008–2024)
The table below shows the annual net assets of Intercure from 2008 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ILA397.67 Million | -12.99% |
| 2023-12-31 | ILA457.06 Million | -12.35% |
| 2022-12-31 | ILA521.48 Million | +13.56% |
| 2021-12-31 | ILA459.19 Million | +57.20% |
| 2020-12-31 | ILA292.11 Million | +14.02% |
| 2019-12-31 | ILA256.20 Million | +1203.03% |
| 2018-12-31 | ILA19.66 Million | -4.92% |
| 2017-12-31 | ILA20.68 Million | -14.08% |
| 2016-12-31 | ILA24.07 Million | +101.36% |
| 2015-12-31 | ILA11.95 Million | +1614.89% |
| 2014-12-31 | ILA697.01K | -82.21% |
| 2013-12-31 | ILA3.92 Million | -60.17% |
| 2012-12-31 | ILA9.84 Million | +119.02% |
| 2011-12-31 | ILA-51.72 Million | -329.82% |
| 2010-12-31 | ILA-12.03 Million | -41.30% |
| 2009-12-31 | ILA-8.52 Million | +55.79% |
| 2008-12-31 | ILA-19.26 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Intercure's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 11056030200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ILA658.60 Million | 165.91% |
| Other Comprehensive Income | ILA15.95 Million | 4.02% |
| Total Equity | ILA396.97 Million | 100.00% |
Intercure Competitors by Market Cap
The table below lists competitors of Intercure ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
MEDIQON Group AG
PINK:MDCKF
|
$367.78K |
|
Sparinvest Bæredy Akt Akk KL A
CO:SPIBDAAKKKLA
|
$368.00K |
|
FLUOR (FLU.SG)
STU:FLU
|
$368.20K |
|
ISHS MSCI GER
BE:ISVP
|
$368.20K |
|
DBT SA
PA:ALDBT
|
$367.36K |
|
MOTOR OIL (HELLAS) (MHZ.SG)
STU:MHZ
|
$367.35K |
|
Setubandhan Infrastructure Limited
NSE:SETUINFRA
|
$367.04K |
|
S+W SEED CO. DL -001
F:210
|
$366.72K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Intercure's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 455,112,000 to 396,969,000, a change of -58,143,000 (-12.8%).
- Net loss of 67,795,000 reduced equity.
- New share issuances of 34,000,000 increased equity.
- Other factors decreased equity by 24,348,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ILA-67.80 Million | -17.08% |
| Share Issuances | ILA34.00 Million | +8.56% |
| Other Changes | ILA-24.35 Million | -6.13% |
| Total Change | ILA- | -12.78% |
Book Value vs Market Value Analysis
This analysis compares Intercure's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 28.01x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | ILA-176.07 | ILA244.00 | x |
| 2012-12-31 | ILA22.52 | ILA244.00 | x |
| 2013-12-31 | ILA2.59 | ILA244.00 | x |
| 2014-12-31 | ILA0.43 | ILA244.00 | x |
| 2015-12-31 | ILA1.35 | ILA244.00 | x |
| 2016-12-31 | ILA1.87 | ILA244.00 | x |
| 2017-12-31 | ILA1.21 | ILA244.00 | x |
| 2018-12-31 | ILA0.95 | ILA244.00 | x |
| 2019-12-31 | ILA10.99 | ILA244.00 | x |
| 2020-12-31 | ILA10.81 | ILA244.00 | x |
| 2021-12-31 | ILA10.97 | ILA244.00 | x |
| 2022-12-31 | ILA11.05 | ILA244.00 | x |
| 2023-12-31 | ILA9.99 | ILA244.00 | x |
| 2024-12-31 | ILA8.71 | ILA244.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Intercure utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -17.08%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -28.38%
- • Asset Turnover: 0.31x
- • Equity Multiplier: 1.92x
- Recent ROE (-17.08%) is above the historical average (-29.49%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 0.00% | -56.35% | 4.13x | 0.00x | ILA-1.63 Million |
| 2012 | 441.63% | 512.95% | 0.58x | 1.48x | ILA42.46 Million |
| 2013 | -168.61% | -80.07% | 1.34x | 1.57x | ILA-7.00 Million |
| 2014 | -544.18% | -67.13% | 2.14x | 3.79x | ILA-3.86 Million |
| 2015 | -15.71% | -134.05% | 0.11x | 1.06x | ILA-3.07 Million |
| 2016 | 1.10% | 0.00% | 0.00x | 1.15x | ILA-2.14 Million |
| 2017 | -25.43% | 0.00% | 0.00x | 1.16x | ILA-7.33 Million |
| 2018 | -65.09% | 0.00% | 0.00x | 1.83x | ILA-14.76 Million |
| 2019 | -2.30% | -66.02% | 0.03x | 1.10x | ILA-31.49 Million |
| 2020 | -13.56% | -57.25% | 0.20x | 1.19x | ILA-64.68 Million |
| 2021 | 1.05% | 2.13% | 0.32x | 1.53x | ILA-40.11 Million |
| 2022 | 8.94% | 11.53% | 0.41x | 1.91x | ILA-5.31 Million |
| 2023 | -13.61% | -17.43% | 0.45x | 1.73x | ILA-107.47 Million |
| 2024 | -17.08% | -28.38% | 0.31x | 1.92x | ILA-107.49 Million |
Industry Comparison
This section compares Intercure's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $14,757,167
- Average return on equity (ROE) among peers: -52.77%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Intercure (INCR) | ILA432.24 Million | 0.00% | 0.74x | $367.38K |
| Canzon Israel Ltd (CNZN) | $7.46 Million | -32.77% | 0.24x | $18.43K |
| Nextage Therapeutics Ltd (NXTG) | $-1.65 Million | 0.00% | 0.00x | $70.01K |
| Rekah Pharmaceutical Industry Ltd (REKA) | $48.86 Million | 18.05% | 3.13x | $385.28K |
| Seach Medical Group Ltd (SEMG) | $-362.00K | 0.00% | 0.00x | $278.78K |
| Together Startup Network Ltd (TGTR) | $1.19 Million | -32.91% | 2.27x | $124.45K |
| Tikun Olam Cannbit Pharmaceuticals Ltd (TKUN) | $33.04 Million | -269.00% | 1.32x | $75.63K |